Recombinant monoclonal antibody siltartoxatug versus plasma-derived human tetanus immunoglobulin for tetanus: a randomized, double-blind, active-controlled, phase 3 trial

Journal:
Nature Medicine
Published:
DOI:
10.1038/s41591-025-03791-8
Affiliations:
29
Authors:
37
Go to article
Institutions Authors Share
Zhuhai Trinomab Biotechnology Co., Ltd., China
9.000000
 0.24
The First Affiliated Hospital, GMU, China
2.000000
 0.05
Peking University First Hospital, PKUHSC, China
1.000000
 0.03
First Affiliated Hospital of Shenzhen University, China
1.000000
 0.03
Affiliated Nanhua Hospital, USC, China
1.000000
 0.03
Affiliated Hospital of ZMU, China
1.000000
 0.03
The Third Affiliated Hospital, GMU, China
1.000000
 0.03
The Second Affiliated Hospital to Nanchang University, China
1.000000
 0.03
Tongji Hospital (TJH), HUST, China
1.000000
 0.03
Liuzhou Workers' Hospital, China
1.000000
 0.03
Second Affiliated Hospital, AHMU, China
1.000000
 0.03
Yuncheng Central Hospital, China
1.000000
 0.03
The First People's Hospital of Jinzhong, China
1.000000
 0.03
Central Hospital of Wuhan, China
1.000000
 0.03
Second Xiangya Hospital, CSU, China
1.000000
 0.03
PKUcare Luzhong Hospital, China
1.000000
 0.03
Zhejiang Provincial People's Hospital, China
1.000000
 0.03
Guangdong Provincial Hospital of Traditional Chinese Medicine, GZUCM, China
1.000000
 0.03
Renmin Hospital of Wuhan University/Hubei General Hospital, China
1.000000
 0.03
Nanfang Hospital, China
1.000000
 0.03
Beijing Tiantan Hospital, Capital Medical University, China
1.000000
 0.03
Hefei First People's Hospital, China
1.000000
 0.03
Hainan General Hospital, China
1.000000
 0.03
The First Affiliated Hospital, SYSU, China
1.000000
 0.03
Second Affiliated Hospital, SCUT, China
1.000000
 0.03
Zhongnan Hospital, WHU, China
1.000000
 0.03
Peking University People's Hospital, PKUHSC, China
1.000000
 0.03
Shanxi Bethune Hospital, China
0.500000
 0.01
Shanxi Medical University (SXMU), China
0.500000
 0.01
Interested in Clinical Sciences?